Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5365
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party ; volume:57 ; number:8 ; day:14 ; month:5 ; year:2022 ; pages:1269-1276 ; date:8.2022
Bone marrow transplantation ; 57, Heft 8 (14.5.2022), 1269-1276, 8.2022
- Creator
-
Duque Afonso, Jesús
Finke, Jürgen
Labopin, Myriam
Craddock, Charles
Protheroe, Rachel
Kottaridis, Panagiotis
Tholouli, Eleni
Byrne, Jenny L.
Orchard, Kim
Salmenniemi, Urpu
Hilgendorf, Inken
Hunter, Hannah
Nicholson, Emma
Bloor, Adrian
Snowden, John A.
Verbeek, Mareike
Clark, Andrew
Savani, Bipin N.
Spyridonidis, Alexandros
Nagler, Arnon
Mohty, Mohamad
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41409-022-01646-1
- URN
-
urn:nbn:de:101:1-2022101919123377696684
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Duque Afonso, Jesús
- Finke, Jürgen
- Labopin, Myriam
- Craddock, Charles
- Protheroe, Rachel
- Kottaridis, Panagiotis
- Tholouli, Eleni
- Byrne, Jenny L.
- Orchard, Kim
- Salmenniemi, Urpu
- Hilgendorf, Inken
- Hunter, Hannah
- Nicholson, Emma
- Bloor, Adrian
- Snowden, John A.
- Verbeek, Mareike
- Clark, Andrew
- Savani, Bipin N.
- Spyridonidis, Alexandros
- Nagler, Arnon
- Mohty, Mohamad
- SpringerLink (Online service)
Other Objects (12)
Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other
Looking Ahead: Clinical Hematology International Turns One
Clinical Hematology International: Why a New Journal in Hematology?
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT
Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the ALWP of the EBMT
Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other
Looking Ahead: Clinical Hematology International Turns One
Clinical Hematology International: Why a New Journal in Hematology?
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT
Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the ALWP of the EBMT
Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other
Looking Ahead: Clinical Hematology International Turns One
Clinical Hematology International: Why a New Journal in Hematology?
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT
Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party